indolent systemic mastocytosis
indolent systemic mastocytosis
Explore linked clinical trials. Standard reference: MONDO:00203316 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany | Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm | Recruiting | Not stated | 2026-10-07 | NCT07255638 | |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-07 | NCT04910685 | |
| (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm | Active, not recruiting | Phase 2 | 2026-10-02 | NCT03731260 | |
| An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) | Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm | Recruiting | Not stated | 2026-09-04 | NCT07264959 | |
| Angioedema Biomarker Research Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Complement Deficiency Diseases, Hypersensitivity, Immediate, Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Primary Immunodeficiency Diseases, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, connective tissue neoplasm, hereditary angioedema, hereditary disease, immune system disorder, inborn error of immunity, indolent systemic mastocytosis, mastocytosis, neoplasm, skin disorder, skin vascular disease, urticaria, vascular disorder | Recruiting | Not stated | 2026-08-24 | NCT06210698 | |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis | Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Mastocytosis, Systemic, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, hematologic disorder, immune system disorder, indolent systemic mastocytosis, mastocytosis, neoplasm, superficial spreading melanoma, type III hypersensitivity disease | Active, not recruiting | Phase 2 | 2026-05-22 | NCT05186753 |